Tue. 19 Mar 2024, 4:33pm ET
Benzinga
Earnings, News
Relmada Therapeutics (NASDAQ:RLMD) reported quarterly losses of $(0.84) per share which missed the analyst consensus estimate of $(0.83) by 1.2 percent. This is a 34.38 percent increase over losses of $(1.28) per share from the same period last year.